Overview

to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban

Status:
RECRUITING
Trial end date:
2026-03-30
Target enrollment:
Participant gender:
Summary
to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban
Phase:
PHASE1
Details
Lead Sponsor:
Onconic Therapeutics Inc.
Treatments:
apixaban
Aspirin
Atorvastatin
Clopidogrel